Being diagnosed with post–polycythemia vera myelofibrosis was scary and difficult for Dan and his wife Carolyn, but there was still hope. Watch his story to see how Jakafi® (ruxolitinib) helped him fight back. Jakafi is a kinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post–polycythemia vera myelofibrosis and post–essential thrombocythemia myelofibrosis. Treatment with Jakafi can cause hematologic adverse reactions, including thrombocytopenia, anemia and neutropenia, which are each dose-related effects, with the most frequent being thrombocytopenia and anemia. Patients should be assessed for the risk of developing serious bacterial, mycobacterial, fungal and viral infections. The three most frequent non-hematologic adverse reactions were bruising, dizziness and headache. Watch the video or visit the Jakafi YouTube page for more information about these and other risks. Please see Full Prescribing Information www.incyte.com
A quote for you...
Powered By Optimism Quotes